| A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2） (NCT07519577) | Keymed Biosciences Co.Ltd | 2026-05-31 |
| Study of CM383 in Healthy Subjects (NCT07292688) | Keymed Biosciences Co.Ltd | 2026-01-01 |
| A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis. (NCT07230483) | Keymed Biosciences Co.Ltd | 2025-12-01 |
| Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU) (NCT07166211) | Keymed Biosciences Co.Ltd | 2025-11-27 |
| A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis (NCT07106372) | Keymed Biosciences Co.Ltd | 2025-09-01 |
| Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients (NCT07181239) | Keymed Biosciences Co.Ltd | 2025-09-01 |
| Study of CM559 in Healthy Subjects (NCT07175506) | Keymed Biosciences Co.Ltd | 2025-09-01 |
| Study of CM313 in Subject With IgA Nephropathy (NCT06830395) | Keymed Biosciences Co.Ltd | 2025-09-01 |
| Study of CM512 Injection in Subjects With Moderate-to-severe Asthma (NCT07011524) | Keymed Biosciences Co.Ltd | 2025-08-19 |
| Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis (NCT07039578) | Keymed Biosciences Co.Ltd | 2025-07-25 |
| Study of CM518D1 in Patients With Advanced Solid Tumors (NCT07019779) | Keymed Biosciences Co.Ltd | 2025-06-27 |
| A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (NCT06980142) | Keymed Biosciences Co.Ltd | 2025-06-20 |
| Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis (NCT06947980) | Keymed Biosciences Co.Ltd | 2025-06-19 |
| Study of Stapokibatrt in Children Subjects With Atopic Dermatitis (NCT06956196) | Keymed Biosciences Co.Ltd | 2025-05-01 |
| Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia (NCT06791824) | Keymed Biosciences Co.Ltd | 2025-03-01 |
| Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE) (NCT06791772) | Keymed Biosciences Co.Ltd | 2025-02-01 |
| Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP) (NCT06594146) | Keymed Biosciences Co.Ltd | 2024-11-11 |
| A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease (NCT06619613) | Keymed Biosciences Co.Ltd | 2024-11-08 |
| Study of Stapokibart Injection in Patients With Allergic Rhinitis (NCT06525597) | Keymed Biosciences Co.Ltd | 2024-09-30 |
| Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis (NCT06553209) | Keymed Biosciences Co.Ltd | 2024-09-02 |
| Study of CM310 in Adolescent Subjects With Atopic Dermatis (NCT06495229) | Keymed Biosciences Co.Ltd | 2024-08-02 |
| Study on the Treatment of Prurigo Nodularis With Stapokibart Injection (NCT06424470) | Keymed Biosciences Co.Ltd | 2024-06-25 |
| Single Dose Escalation Study of CM383 in Healthy Volunteers (NCT06412185) | Keymed Biosciences Co.Ltd | 2024-05-28 |
| Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects (NCT06171048) | Keymed Biosciences Co.Ltd | 2024-04-30 |
| Study of CM310 in Subjects With Seasonal Allergic Rhinitis (NCT06171074) | Keymed Biosciences Co.Ltd | 2024-03-30 |
| A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis (NCT06116565) | Keymed Biosciences Co.Ltd | 2024-03-30 |
| Study of CM313 in Healthy Subjects (NCT06285227) | Keymed Biosciences Co.Ltd | 2024-03-12 |
| A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma (NCT06126237) | Keymed Biosciences Co.Ltd | 2024-02-28 |
| Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis (NCT06162507) | Keymed Biosciences Co.Ltd | 2023-12-22 |
| Study of CM310 in Patients With Allergic Rhinitis (NCT05908721) | Keymed Biosciences Co.Ltd | 2023-08-23 |
| Study of CM310 in Subjects With Allergic Rhinitis (NCT05908032) | Keymed Biosciences Co.Ltd | 2023-08-10 |
| Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy (NCT05775042) | Keymed Biosciences Co.Ltd | 2023-05-08 |
| Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310 (NCT05702450) | Keymed Biosciences Co.Ltd | 2023-03-22 |
| Study of CM326 Injection in Healthy Subjects (NCT05715333) | Keymed Biosciences Co.Ltd | 2023-03-21 |
| The Study of CM326 in Adult Subjects With Atopic Dermatitis (NCT05671445) | Keymed Biosciences Co.Ltd | 2023-02-09 |
| The Study of CM326 in Moderate-to-severe Atopic Dermatitis (NCT05671432) | Keymed Biosciences Co.Ltd | 2022-12-27 |
| A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus (NCT05465707) | Keymed Biosciences Co.Ltd | 2022-10-30 |
| A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis (NCT05579925) | Keymed Biosciences Co.Ltd | 2022-10-07 |
| A Study of CM310 in Subjects With Chronic Pruritus (NCT05452343) | Keymed Biosciences Co.Ltd | 2022-08-30 |
| A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （CROWNS-2） (NCT05436275) | Keymed Biosciences Co.Ltd | 2022-08-09 |
| A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma (NCT05299424) | Keymed Biosciences Co.Ltd | 2022-08-09 |
| A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps (NCT05324137) | Keymed Biosciences Co.Ltd | 2022-07-11 |
| Multiple Ascending Dose Study of CM338 in Healthy Volunteers (NCT05371379) | Keymed Biosciences Co.Ltd | 2022-05-24 |
| A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (NCT05265923) | Keymed Biosciences Co.Ltd | 2022-04-22 |
| The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis (NCT05186922) | Keymed Biosciences Co.Ltd | 2022-02-17 |
| A Study of CM310 in Subjects With Moderate to Severe Asthma (NCT05186909) | Keymed Biosciences Co.Ltd | 2022-01-12 |
| A Multiple Ascending Doses Study of CM326 Injection in Healthy Subjects (NCT05171348) | Keymed Biosciences Co.Ltd | 2022-01-07 |
| Single Ascending Dose Study of CM338 in Healthy Volunteers (NCT05186285) | Keymed Biosciences Co.Ltd | 2021-12-11 |
| The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps (NCT05131464) | Keymed Biosciences Co.Ltd | 2021-11-30 |
| The Study of CM310 in Patients With Atopic Dermatitis (NCT04893707) | Keymed Biosciences Co.Ltd | 2021-06-07 |
| Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma (NCT04818372) | Keymed Biosciences Co.Ltd | 2021-04-26 |
| Single Ascending Dose Study of CM326 in Healthy Volunteers (NCT04842201) | Keymed Biosciences Co.Ltd | 2021-04-13 |
| Subcutaneously CM310/Placebo in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-1) (NCT04805398) | Keymed Biosciences Co.Ltd | 2021-04-06 |
| Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD) (NCT04805411) | Keymed Biosciences Co.Ltd | 2021-02-24 |
| Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 (NCT04805307) | Keymed Biosciences Co.Ltd | 2020-12-24 |
| Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD) (NCT04893941) | Keymed Biosciences Co.Ltd | 2020-07-21 |
| Study of CM310 in Healthy Subjects (NCT06161090) | Keymed Biosciences Co.Ltd | 2019-09-03 |